High Rates of Escalation and Termination of Adalimumab Therapy and Patients Exposed to Infliximab

Mazen Issa; Yelena Zadvornova; Amar S. Naik; Dan Joseph Stein; Nanda Venu; Lilani P. Perera

doi:10.1016/s0016-5085(11)62433-5

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2018

Optimizing therapy in bortezomib-exposed patients with multiple myeloma

Magdalini Migkou, Maria Gavriatopoulou, Evangelos Terpos, Meletios A Dimopoulos

Article2017

Accelerated Dosing of Infliximab Is Not Associated With Improved Colectomy Rates in Hospitalized Severe Ulcerative Colitis Patients

Nichole Sly, Shannon L. Werner, Renee D. Pitt, Ruta Bajorunaite, Lisa Rein, Dan Joseph Stein

Article2006

Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial

Kristian Reich, Frank O. Nestlé, Kim Papp, J.‐P. Ortonne, Yifang Wu, M Bala, Robert J. Evans, Cynthia Guzzo, Shuangyue Li, Lisa T. Dooley, Christopher Em Griffiths

Article2009

Impact of prior irregular infliximab dosing on performance of long-term infliximab maintenance therapy in Crohn's disease†

Dan Joseph Stein, Ashwin N. Ananthakrishnan, Mazen Issa, John B. Williams, Dawn B. Beaulieu, Yelena Zadvornova, Anita Ward, Kathryn Johnson, Josh F. Knox, Sue Skaros, David G. Binion

Article2010

Skin and Nail Responses after 1 Year of Infliximab Therapy in Patients with Moderate-to-Severe Psoriasis: A Retrospective Analysis of the EXPRESS Trial

Kristian Reich, Jean-Paul Ortonne, Urs Kerkmann, Yanxin Wang, J.‐H. Saurat, Kim Papp, Richard G. Langley, Christopher Em Griffiths